» Articles » PMID: 21078106

Psychiatric Symptoms and Health-related Quality of Life in Children and Adolescents with Psoriasis

Overview
Publisher Wiley
Specialties Dermatology
Pediatrics
Date 2010 Nov 17
PMID 21078106
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Information about the relationship between psoriasis and psychiatric morbidity and quality of life in children and adolescents is limited. We aimed to examine the symptoms of depression and anxiety and health-related quality of life levels in children and adolescents with psoriasis. Forty-eight outpatients with psoriasis aged 8 to 18 years are included in this study. Child Depression Inventory (CDI), State-Trait Anxiety Inventories for Children (STAI-C) and Pediatric Quality of Life Inventory Parent and Child Versions (PedQL-P and C) were applied to both patient and control groups. Psoriasis symptom severity was measured by the Psoriasis Area Severity Index (PASI). Both study and control groups were divided into two age groups, child (8-12 yrs) and adolescent (13-18 yrs), to exclude the effect of puberty on psychological condition. The mean CDI score was higher, and PedQL-C psychosocial and total scores were lower in the children compared with controls. Duration of psoriasis had an increasing effect on physical-health and total scores of PedQL-C in the child group and all PedQL-C scores in the entire sample. Psoriasis severity showed a negative correlation with psychosocial and total scores of PedQL-P in the adolescent group and PedQL-P physical-health scores in the entire sample. Psoriasis is related to depression and impaired quality of life in children. The depressive symptoms in children with psoriasis should not be overlooked and psychiatric assessment of these children should be provided.

Citing Articles

Topical Management of Pediatric Psoriasis: A Review of New Developments and Existing Therapies.

Lie E, Choi M, Wang S, Eichenfield L Paediatr Drugs. 2023; 26(1):9-18.

PMID: 37847480 PMC: 10769900. DOI: 10.1007/s40272-023-00592-9.


Impact of Childhood Onset Psoriasis on Addictive Behaviours, Socioeconomic and Educational Data in Adulthood.

Mahe E, Tubach F, Jullien D, Tran D, Paul C, Beylot-Barry M Acta Derm Venereol. 2022; 102:adv00733.

PMID: 35506359 PMC: 9593492. DOI: 10.2340/actadv.v102.2484.


Halobetasol propionate lotion 0.05% in patients 12 to 16 years 11 months of age with plaque psoriasis: Results of an open-label study evaluating adrenal suppression potential.

Laquer V, Nguyen A, Squittieri N, Nguyen T JAAD Int. 2021; 6:13-19.

PMID: 34870246 PMC: 8626834. DOI: 10.1016/j.jdin.2021.10.003.


Prevalence and patient-reported outcomes of noncommunicable skin diseases among college students in China.

Shen M, Xiao Y, Su J, Zhao S, Li J, Tao J JAAD Int. 2021; 1(1):23-30.

PMID: 34409315 PMC: 8361873. DOI: 10.1016/j.jdin.2020.03.003.


Optimal Management of Plaque Psoriasis in Adolescents: Current Perspectives.

Mahe E Psoriasis (Auckl). 2020; 10:45-56.

PMID: 33274179 PMC: 7708777. DOI: 10.2147/PTT.S222729.